MCKESSON CORPORATION |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 578.7 USD | +0.87% |
|
+3.68% | +25.16% |
| Jun. 03 | Mckesson Insider Sold Shares Worth $2,935,100, According to a Recent SEC Filing | MT |
| Jun. 03 | Mckesson Corporation Elects Deborah Dunsire as New Director | CI |
Financials (USD)
| Sales 2025 * | 358B | Sales 2026 * | 388B | Capitalization | 74.58B |
|---|---|---|---|---|---|
| Net income 2025 * | 3.7B | Net income 2026 * | 3.92B | EV / Sales 2025 * | 0.21 x |
| Net cash position 2025 * | 161M | Net cash position 2026 * | 3.01B | EV / Sales 2026 * | 0.18 x |
| P/E ratio 2025 * |
19.6
x | P/E ratio 2026 * |
17.9
x | Employees | 48,000 |
| Yield 2025 * |
0.47% | Yield 2026 * |
0.5% | Free-Float | 46.71% |
More Fundamentals
* Assessed data
More news
Latest transcript on McKesson Corporation
More recommendations
More press releases
More news
| 1 day | +0.77% | ||
| 1 week | +3.35% | ||
| Current month | +1.41% | ||
| 1 month | +8.29% | ||
| 3 months | +9.23% | ||
| 6 months | +25.36% | ||
| Current year | +24.76% |
1 week
558.40
578.69
1 month
530.80578.69
Current year
462.70578.69
1 year
383.82578.69
3 years
184.43578.69
5 years
112.60578.69
10 years
106.11578.69
| Managers | Title | Age | Since |
|---|---|---|---|
Brian Tyler
CEO | Chief Executive Officer | 57 | 11-12-31 |
| Director of Finance/CFO | 55 | 18-01-26 | |
Francisco Fraga
CTO | Chief Tech/Sci/R&D Officer | 51 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Donald Knauss
CHM | Chairman | 73 | 14-10-19 |
Webster Dunbar
BRD | Director/Board Member | 62 | 22-03-31 |
| Director/Board Member | 66 | 22-01-12 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.43% | 9 M€ | -.--% | ||
| 2.31% | 1,085 M€ | +9.24% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-05 | 579.7 | +1.04% | 236 125 |
| 24-06-04 | 573.7 | +0.10% | 488,706 |
| 24-06-03 | 573.2 | +0.63% | 1,055,931 |
| 24-05-31 | 569.6 | +1.54% | 1,165,435 |
| 24-05-30 | 561 | +0.37% | 599,204 |
Delayed Quote Nyse, June 05, 2024 at 12:58 pm EDT
More quotes
McKesson Corporation specializes in pharmaceutical product distribution. The group also offers technological services to healthcare companies. Net sales break down by activity as follows:
- distribution of pharmaceutical products (87%);
- distribution of medical and surgical products (4%);
- other (1.6%): primarily technology services and software sales.
The remaining net sales (7.4%) are from international activities.
Sector
Pharmaceuticals
Calendar
2024-07-30
- Q1 2025 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
573.7
USD
Average target price
589.5
USD
Spread / Average Target
+2.75%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +24.76% | 74.58B | |
| -2.99% | 23.95B | |
| +5.38% | 8.55B | |
| +10.64% | 8.52B | |
| -22.31% | 7.85B | |
| +11.90% | 5.18B | |
| +1.86% | 4.17B | |
| -5.04% | 4.06B | |
| +3.71% | 3.89B | |
| +21.59% | 3.65B |
- Stock Market
- Equities
- MCK Stock
